[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355160-105":59,"doc-detail-355160-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-utility-of-the-apolipoprotein-a2-isoform-index-as-a-tumor-marker-for-pancreatic-cancer","Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer","","Background and Aims: The study evaluates the clinical utility of the apolipoprotein A2 isoform index (apoA2-i index), focusing on CA19-9-negative pancreatic cancer. Methods: Between May 2024 and July 2025, abdominal CT patients received measurements of CEA, CA19-9, and apoA2-i index; sensitivity and specificity for pancreatic cancer were assessed. Results: In 115 patients, apoA2-i showed 65.8% sensitivity and 85.7% specificity; combined marker testing increased sensitivity to 78.9%. Lower apoA2-i values correlated with pancreatic atrophy and pancreatic duct dilatation. Conclusions: The apoA2-i index detects CA19-9-negative disease and improves diagnostic performance when combined with CA19-9.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-utility-of-the-apolipoprotein-a2-isoform-index-as-a-tumor-marker-for-pancreatic-cancer/355160/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-utility-of-the-apolipoprotein-a2-isoform-index-as-a-tumor-marker-for-pancreatic-cancer/355160.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the apoA2-i index and what clinical utility is investigated in this study?","Question",{"text":112,"@type":113},"The apoA2-i index is a novel tumor marker for pancreatic cancer. The study assesses its diagnostic utility in routine practice, especially for CA19-9-negative pancreatic cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were sensitivity and specificity evaluated?",{"text":117,"@type":113},"Patients who underwent abdominal CT for pancreatic disease differential diagnosis had CEA, CA19-9, and apoA2-i index measured. The study evaluated sensitivity and specificity for identifying pancreatic cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the apoA2-i index perform for CA19-9-negative pancreatic cancer?",{"text":121,"@type":113},"Among 17 CA19-9-negative pancreatic cancer patients, 9 (52.9%) were positive for the apoA2-i index. Positive rates differed by stage, with stage 0/I showing higher positivity for apoA2-i than CA19-9.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355160,1790493308,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","JGH Open  \nORIGINAL ARTICLE  OPEN ACCESS   \nClinical Utility ofthe Apolipoprotein A2 Isoform Index asa Tumor Marker for Pancreatic Cancer  \nTakashi Hoshino1 | Masafumi Mizuide2  | Yuhei Suzuki1 | Hidetoshi Yasuoka1 | Atsushi Naganuma1  | Takeshi Hatanaka3  | Satoru Kakizaki1,4  | Shomei Ryozawa2   \n1Department of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan | 2Department of Gastroenterology, Saitama Medical University International Medical Center, Hidaka, Japan | 3Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan | 4Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan  \nCorrespondence: Satoru Kakizaki ([kakizaki@gunma-u.ac.jp](kakizaki@gunma-u.ac.jp))  \nReceived: 24 November 2025 | Revised: 10 February 2026 | Accepted: 13 February 2026  \nKeywords: apolipoprotein A2 isoform index | CA19-9 | Lewis antigen | pancreatic cancer | tumor marker  \nABSTRACT  \nBackground and Aims: We investigated the clinical utility of the apolipoprotein A2 isoform index (apoA2-i index), a novel tumor marker for pancreatic cancer, in clinical practice, particularly for CA19-9-negative pancreatic cancer.  \nMethods: Between May 2024 and July 2025, patients who underwent abdominal computed tomography (CT) for the differential diagnosis of pancreatic diseases had their CEA, CA19-9, and apoA2-i indexes measured. We evaluated the sensitivity and specificity for pancreatic cancer and analyzed the relationship between the apoA2-i index and pancreatic atrophy or main pancreatic duct dilatation on CT.  \nResults: A total of 115 patients were included: 38 with pancreatic cancer, 47 with intraductal papillary mucinous neoplasms (IPMNs), and 30 with other conditions. The median age was 72.0 years, and 55 patients (47.8%) were male. The sensitivity of apoA2-i index for pancreatic cancer was 65.8%, while the specificity was 85.7% . The combined use of CA19-9 and the apoA2-i index increased sensitivity to 78.9%(specificity, 81.8%) . Among 17 patients with CA19-9-negative pancreatic cancer, 9 (52.9%) tested positive for the apoA2-i index. The positive rates for stage 0/I pancreatic cancer were 12.5% for CA19-9 and 62.5% for theapoA2-i index. Regarding CT findings, the apoA2-i index significantly decreased with the progression of pancreatic atrophy (p = 0.027) and was also significantly lower in patients with pancreatic duct dilatation (p = 0.016) .  \nConclusions: The apoA2-i index can detect CA19-9-negative pancreatic cancer, and the combination of the apoA2-i index with CA19-9 enhances diagnostic performance in clinical practice.  \n1 | Introduction  \nPancreatic cancer is one of the leading causes of cancer-related deaths worldwide and carries one of the poorest prognoses among gastrointestinal malignancies [1] . In Japan, it is the third most common cause of cancer death, with age-adjusted incidence and mortality steadily increasing over recent decades [2] . Although early-stage diagnosis and surgical resection have improved outcomes [1, 3], most cases are already advanced and inoperable at the time of diagnosis. Because early-stage pancreatic  \ncancer is often asymptomatic, delayed diagnosis remains a major problem, highlighting the urgent need for reliable tools for early detection, including effective tumor markers.  \nCA19-9 is the most widely used tumor marker in clinical practice [4], but it has important limitations. False-positive elevations occur in benign conditions such as biliary obstruction, cholangitis, and liver disease [5]. In addition, some patients have CA19-9-negative pancreatic cancer, partly due to Lewis antigen deficiency because CA19-9 synthesis depends on Lewis antigen expression;  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). JGH Open published by Journal of Gastroenterology an","cbCaip3fO2fHt6WF","https://ap.wps.com/l/cbCaip3fO2fHt6WF","pdf",753888,"English","# Abstract\n## Background and Aims\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Patients and Methods\n## Patients","[{\"question\":\"What is the apoA2-i index and what clinical utility is investigated in this study?\",\"answer\":\"The apoA2-i index is a novel tumor marker for pancreatic cancer. The study assesses its diagnostic utility in routine practice, especially for CA19-9-negative pancreatic cancer.\"},{\"question\":\"How were sensitivity and specificity evaluated?\",\"answer\":\"Patients who underwent abdominal CT for pancreatic disease differential diagnosis had CEA, CA19-9, and apoA2-i index measured. The study evaluated sensitivity and specificity for identifying pancreatic cancer.\"},{\"question\":\"How does the apoA2-i index perform for CA19-9-negative pancreatic cancer?\",\"answer\":\"Among 17 CA19-9-negative pancreatic cancer patients, 9 (52.9%) were positive for the apoA2-i index. Positive rates differed by stage, with stage 0/I showing higher positivity for apoA2-i than CA19-9.\"}]","Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer | PDF",1790116409,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6808348534ed50331620d8a2cdf896a.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/511e67568f93711bc8453712cfdd6ada.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bdba901ab9b1d71a20c14406db56e88.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5865c2b5a5ed80184c95fcf5a1c6abe0.webp",980,1287]